<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04701580</url>
  </required_header>
  <id_info>
    <org_study_id>s61478</org_study_id>
    <nct_id>NCT04701580</nct_id>
  </id_info>
  <brief_title>Synaptic Density and Progression of Huntington's Disease.</brief_title>
  <official_title>Longitudinal Measurement of Synaptic Density to Monitor Progression of Huntington's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AIM: To assess synaptic density and to investigate the potential relationship of regional&#xD;
      synaptic loss with motor and non-motor symptoms and with disease progression in the human&#xD;
      brain in vivo in patients with HD.&#xD;
&#xD;
      DESIGN: The investigators will include 20 HD mutations carriers and 15 healthy controls. All&#xD;
      subjects will undergo a clinical examination, with comprehensive assessment of motor and&#xD;
      non-motor symptoms, and imaging evaluation consisting of 11C-UCB-J PET-CT and 18F-FDG PET-MR&#xD;
      at baseline and after 2 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Longitudinal study design (2 years follow up) where results of SV2A PET/CT, FDG PET/MR and clinical rating scales are compared between HD patients and healthy controls.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline differences in synaptic density.</measure>
    <time_frame>Data analysis wel be done when all subjects have undergone the baseline evaluation.</time_frame>
    <description>Baseline differences (%) in (regional) synaptic density between patients and controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline correlations between clinical scores and regional synaptic density.</measure>
    <time_frame>Data analysis wel be done when all subjects have undergone the baseline evaluation.</time_frame>
    <description>Correlations between clinical scores and regional synaptic density in the patient group at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences in the rate of decline of synaptic density.</measure>
    <time_frame>Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.</time_frame>
    <description>Differences (%) in the rate of decline of synaptic density between patients and controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlations between progression of the clinical scores and decline of synaptic density.</measure>
    <time_frame>Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.</time_frame>
    <description>Correlations between progression of the clinical scores and decline of synaptic density in the patient group, after longitudinal follow up of 2 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline differences in cerebral glucose metabolism.</measure>
    <time_frame>Data analysis wel be done when all subjects have undergone the baseline evaluation.</time_frame>
    <description>Baseline differences (%) in (regional) glucose metabolism between patients and controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline correlations between clinical scores and cerebral glucose metabolism.</measure>
    <time_frame>Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.</time_frame>
    <description>Correlations between clinical scores and cerebral glucose metabolism in the patient group at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in the rate of decline of cerebral glucose metabolism.</measure>
    <time_frame>Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.</time_frame>
    <description>Differences (%) in the rate of decline in cerebral glucose metabolism between patients and controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations between progression of the clinical scores and decline of cerebral glucose metabolism in the patient group, after longitudinal follow up of 2 years.</measure>
    <time_frame>Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.</time_frame>
    <description>Correlations between progression of the clinical scores and decline of cerebral glucose metabolism in the patient group, after longitudinal follow up of 2 years.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>HD patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At baseline and 2-year follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At baseline and 2-year follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>11C-UCB-J PET-CT</intervention_name>
    <description>Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.</description>
    <arm_group_label>HD patients</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>18F-FDG PET-MR</intervention_name>
    <description>Positron Emission Tomography (PET) of glucose metabolism using the radioligand 18F-FDG, and brain MRI performed simultaneously.</description>
    <arm_group_label>HD patients</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 20-75 years.&#xD;
&#xD;
          -  Capacity to understand the informed consent form.&#xD;
&#xD;
          -  For HD group: CAG repeat expansion in HTT â‰¥ 40.&#xD;
&#xD;
          -  Premanifest HD mutation carriers:&#xD;
&#xD;
             * No clinical diagnostic motor features of HD, defined as Unified Huntington's Disease&#xD;
             Rating Scale (UHDRS) Diagnostic Confidence Score &lt; 4.&#xD;
&#xD;
          -  Early manifest HD patients:&#xD;
&#xD;
               -  Clinical diagnostic motor features of HD, defined as Unified Huntington's Disease&#xD;
                  Rating Scale (UHDRS) Diagnostic Confidence Score = 4.&#xD;
&#xD;
               -  UHDRS-TFC score 7 or higher (Shoulson-Fahn stage 1 and 2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  neuropsychiatric diseases other than HD&#xD;
&#xD;
          -  major internal medical diseases&#xD;
&#xD;
          -  white matter lesion load on FLAIR Fazekas score 2 or higher or other relevant MRI&#xD;
             abnormalities&#xD;
&#xD;
          -  history of alcohol abuse or current alcohol abuse (chronic use of more than 15 units&#xD;
             per week) or drug abuse&#xD;
&#xD;
          -  contraindications for MR&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  previous participation in other research studies involving ionizing radiation with &gt;1&#xD;
             mSv in the previous 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wim Vandenberghe, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Huntington Disease</keyword>
  <keyword>PET</keyword>
  <keyword>11C-UCB-J</keyword>
  <keyword>18F-FDG</keyword>
  <keyword>SV2A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Needs to be decided.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

